Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study
Diabetes Research and Clinical Practice Mar 04, 2018
Keyany A, et al. - Experts coveted an investigation of the correlation between parenteral glucocorticoids (GCs) use and the risk of receiving a first prescription of a non-insulin antidiabetic drug (NIAD) as a proxy for new onset of type 2 diabetes mellitus (T2DM). Findings disclosed that there was no link between the use of parenterally administered GCs and the risk of receiving a first prescription of a NIAD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
